This is a scientific update with no immediate financial or regulatory impact. The stock has historically underperformed following similar data releases (avg T+20 -5.41%). Traders should watch for any subsequent regulatory or commercial developments, but this press release alone is unlikely to be a catalyst.
Price Chart
Executive Summary
Amarin announced a post-hoc analysis from the REDUCE-IT trial at ESC 2026, showing that highly adherent patients on icosapent ethyl (IPE) experienced ~30% relative risk reduction in MACE, and that benefits may persist for years after discontinuation (legacy effect). This is a scientific update on an already-approved drug, not a regulatory catalyst or new revenue driver, and does not change the company's commercial outlook or financial position.
Key Facts
- Post-hoc analysis of REDUCE-IT showed ~30% RRR in primary endpoint for high adherers on IPE for ≥1.5 years.
- Secondary prevention patients who stopped IPE after mean 2.3 years maintained HR of 0.73 for events occurring after discontinuation (legacy effect).
- The analysis is exploratory and presented at ESC 2026; no new regulatory or commercial catalyst.
- Amarin's market cap is ~$297M with 0% analyst bullishness and recent insider selling.
- Historical reports on AMRN show a -5.41% average T+20 return and 40% win rate, indicating the stock has not responded positively to prior similar updates.
Financial Impact
No financial figures reported; the analysis does not change revenue, earnings, or guidance.
Risk Factors
- No new revenue or regulatory catalyst; the analysis is exploratory and does not change the commercial outlook.
- Historical underperformance on similar updates suggests limited positive price reaction.
- Low analyst bullishness (0%) and recent insider selling indicate weak sentiment.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3352671 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 28, 2026 5w ago | Press Release | $13.97 $13.25 | ▼ −5.15% | ▼ −5.41% | $12.60 (−9.84%) |
Jun 4, 2026 17w ago | Court Ruling | $13.80 $16.37 | ▼ −18.62% | ▼ −20.00% | $12.60 (+8.73%) |
Apr 29, 2026 22w ago | 8-K | $14.29 $14.41 | ▲ +0.84% | ▼ −5.21% | $12.60 (−11.86%) |
Mar 16, 2026 28w ago | Press Release | $15.42 $14.55 | ▼ −5.64% | ▼ −9.42% | $12.60 (−18.32%) |
Feb 25, 2026 31w ago | 8-K | $14.05 $14.68 | ▼ −4.48% | ▼ −9.72% | $12.60 (+10.36%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access